Please use this identifier to cite or link to this item:
https://islhd.intersearch.com.au/islhdjspui/handle/1/5534
Title: | Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre open-label global phase 3 randomised controlled trial |
ISLHD Author: | Clingan, Philip |
Authors: | Sezer A;Kilickap S;Gümüş M;Bondarenko I;Özgüroğlu M;Gogishvili M;Turk HM;Cicin I;Bentsion D;Gladkov O;Clingan P;Sriuranpong V;Rizvi N;Gao B;Li S;Lee S;McGuire K;Chen CI;Makharadze T;Paydas S;Nechaeva M;Seebach F;Weinreich DM;Yancopoulos GD;Gullo G;Lowy I;Rietschel P. |
Keywords: | Pharmacology;Oncology |
Date Published: | 14-Feb-2021 |
Citation: | Lancet. 2021 Feb 13;397(10274):592-604. doi: 10.1016/S0140-6736(21)00228-2. |
URI: | https://islhd.intersearch.com.au/islhdjspui/handle/1/5534 |
Appears in Collections: | Research publications from current and former ISLHD staff. |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.